Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

糖尿病肾病：药物发现和临床开发挑战

• 批准号: 8785323
• 负责人: Frank C Brosius
• 金额: $ 1万
• 依托单位: NEW YORK ACADEMY OF SCIENCES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8785323
• 关键词: Academia; Academy; Albuminuria; Angiotensins; Animal Model; Anti-Inflammatory Agents; Anti-inflammatory; Area; Award; Basic Science; Benefits and Risks; Biological Markers; Blood capillaries; Caring; Cells; Child; Chronic Kidney Failure; Clinic; Clinical; Clinical Data; Clinical Investigator; Clinical Trials; Collaborations; Communities; Complications of Diabetes Mellitus; Congresses; Consensus; Coupled; Data; Development; Diabetes Mellitus; Diabetic Nephropathy; Diagnostic; Digestive System Disorders; Disabled Persons; Disease; Disease Association; Drug Industry; Educational workshop; End stage renal failure; Epidemic; Event; Faculty; Family; Fellowship; Female; Fibrosis; Fostering; Future; Goals; Government; Healthcare Systems; Incidence; Industry; Inflammation; Institutes; International; Kidney; Kidney Diseases; Knowledge; Life; Medical Research; Mentors; Metabolism; Minority Groups; Mission; Molecular; Monitor; Multimedia; New York; New York City; Obesity; Participant; Pathway interactions; Patients; Pharmacologic Substance; Physiology; Pre-Clinical Model; Prevalence; Process; Prognostic Marker; Progressive Disease; Public Health; Publications; Publishing; Research; Research Personnel; Research Training; Resolution; Risk; Role; Science; Scientist; Signal Pathway; Signal Transduction; Technical Expertise; Technology; Therapeutic; Tissues; Translational Research; Translations; Travel; Tubular formation; Underrepresented Minority; United States; Woman; abstracting; advanced disease; base; capillary; career; cell type; data exchange; discount; drug candidate; drug development; drug discovery; improved; innovation; insight; knowledge translation; lectures; mTOR inhibition; meetings; new technology; new therapeutic target; novel; novel therapeutics; outcome forecast; posters; prevent; public health relevance; repository; standard of care; symposium; targeted delivery; treatment strategy

DESCRIPTION (provided by applicant): Diabetic nephropathy (DN), a well-known complication of diabetes, is the leading cause of chronic renal failure and end-stage renal disease (ESRD). The limited efficacy of the standard of care, which only delays the progression to ESRD to a limited extent, coupled with our incomplete understanding of this multifaceted disease, highlights the importance of unraveling novel therapeutic targets. This 1-day scientific symposium titled, "Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges" will be presented by the New York Academy of Sciences on December 9, 2014, in New York City. This symposium will blend new technologies, target-disease associations, physiology-based insights, and identify novel targets, with the goals of identifying and delivering novel drug candidates into the clinic, improving current treatments, and developing new therapeutic strategies. The event will convene approximately 150 attendees ranging from basic scientists and clinical investigators in academia, industry, and government; to pharmaceutical strategists, and regulatory experts. The three central aims of this conference are to: (i) provide neutral forum through lectures, interactive debates, and networking activities for discussing current hurdles and emerging innovative approaches to DN-targeted therapy, such as preclinical models and clinical trials, signaling pathways, identification of druggable targets, capillary loss and excess anti-angiogenic activity associated with advanced disease states, and targeting the renal microvasculature; (ii) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations, travel fellowships, career mentoring activities, and discounted registration; and (iii) foster collaboratin among international investigators from all sectors to promote the translation of research into safer and more efficient diabetic kidney disease therapeutics. The symposium goals align well with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to support medical research and research training. The NIDDK's goal to disseminate science-based information on diabetes and kidney diseases will be met through the symposium's simulcast and archival as a webinar and open-access, online, multimedia Academy eBriefing, and publication of an open-access, Section 508- compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the symposium to the global research and medical communities. This symposium is especially timely given that a wealth of new data has emerged within distinct research areas (e.g., novel cell types, targets, and therapies) and from varied scientific approaches (e.g., animal models, novel target tissues). A collaborative examination of this new information among all diabetic kidney disease stakeholders is therefore of significant value for guiding research forward in the field - particularly with respect to potential novel targets and delivery of novel drug candidates into the clinic.

描述（由申请人提供）：糖尿病肾病（DN）是一种众所周知的糖尿病并发症，是慢性肾功能衰竭和终末期肾病（ESRD）的主要原因。标准治疗的有限疗效，仅在有限程度上延迟了ESRD的进展，加上我们对这种多面疾病的不完全了解，突出了揭示新的治疗靶点的重要性。这个为期1天的科学研讨会名为“糖尿病肾病：药物发现和临床开发挑战”，将由纽约科学院于2014年12月9日在纽约市举行。本次研讨会将融合新技术，靶标疾病关联，基于生理学的见解，并确定新的靶标，目标是识别和交付